How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience

Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.

Authors

Dario Ferrero¹, Marco Cerrano¹, Elena Crisà¹, Chiara Aguzzi¹, Valentina Giai¹, Mario Boccadoro¹

Affiliation

¹ Haematology Division, Università degli Studi di Torino, Turin, Italy.

PMID: 26914729
DOI: 10.1111/bjh.13983

No abstract available

Keywords: chronic myeloid leukaemia; imatinib discontinuation; treatment cessation; tyrosine kinase inhibitor.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Follow-Up Studies
Humans
Imatinib Mesylate / administration & dosage
Imatinib Mesylate / adverse effects
Imatinib Mesylate / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Prognosis
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate